Inovio Pharma Reports Positive Responses in HIV Vaccine Trial

By Features FOXBusiness

Inovio Pharmaceuticals (INO) said on Tuesday that its global HIV vaccine has demonstrated strong immune responses and safety in an early-stage study.

Continue Reading Below

The Blue Bell, Pa.-based maker of vaccines against cancer and infectious diseases presented the early results of the first-stage study at the AIDS Vaccine Conference in Bangkok.

Early analysts of the initial data revealed a strong cell-mediated immune response for both the gag and env antigens encoded by the prime and boost agents, the company said.

All patients in the study showed anti-env CD+ T-cell immune responses, and Inovio CEO Dr. Joseph Kim said the company believes a 100% vaccine induced env-specific t-cell immune response result has never before been achieved in HIV vaccine trials.

We are pleased to see the response rate and magnitude of T-cell responses generated by the prime-boost vaccine combination, Kim said in a statement.

The study is being conducted by the U.S. Military HIV Research Program and is being sponsored by the National Institute of Allergy and Infectious diseases.